1. Home
  2. KEN vs NAMS Comparison

KEN vs NAMS Comparison

Compare KEN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenon Holdings Ltd.

KEN

Kenon Holdings Ltd.

HOLD

Current Price

$66.80

Market Cap

3.6B

Sector

Utilities

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$27.45

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEN
NAMS
Founded
2014
2019
Country
Singapore
Netherlands
Employees
N/A
100
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KEN
NAMS
Price
$66.80
$27.45
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$46.75
AVG Volume (30 Days)
15.3K
883.5K
Earning Date
05-27-2026
05-06-2026
Dividend Yield
4.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
$9.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.50
$21.23
52 Week High
$95.93
$42.21

Technical Indicators

Market Signals
Indicator
KEN
NAMS
Relative Strength Index (RSI) 46.49 35.97
Support Level $65.67 N/A
Resistance Level $71.01 $37.29
Average True Range (ATR) 1.38 1.80
MACD 0.30 -0.50
Stochastic Oscillator 46.79 9.74

Price Performance

Historical Comparison
KEN
NAMS

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: